Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer.
Identifieur interne : 000131 ( Main/Exploration ); précédent : 000130; suivant : 000132Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer.
Auteurs : Dinghu Zhang [République populaire de Chine] ; Yanhong Chu [République populaire de Chine] ; Hanqing Qian [République populaire de Chine] ; Lingyu Qian [République populaire de Chine] ; Jie Shao [République populaire de Chine] ; Qiuping Xu [République populaire de Chine] ; Lixia Yu [République populaire de Chine] ; Rutian Li [République populaire de Chine] ; Quanan Zhang [République populaire de Chine] ; Fenglei Wu [République populaire de Chine] ; Baorui Liu [République populaire de Chine] ; Qin Liu [République populaire de Chine]Source :
- International journal of nanomedicine [ 1178-2013 ] ; 2020.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Antinéoplasiques (pharmacologie), Antinéoplasiques (usage thérapeutique), Bombyx (MeSH), Distribution tissulaire (MeSH), Dérivés de l'hypromellose (composition chimique), Fibroïne (composition chimique), Glycérol (composition chimique), Humains (MeSH), Hydrogels (composition chimique), Lignée cellulaire tumorale (MeSH), Mâle (MeSH), Nanoparticules (composition chimique), Nanoparticules (ultrastructure), Oligopeptides (pharmacologie), Porosité (MeSH), Souris de lignée BALB C (MeSH), Souris nude (MeSH), Température (MeSH), Tumeurs de l'estomac (anatomopathologie), Tumeurs de l'estomac (traitement médicamenteux), Xanthones (pharmacologie), Xanthones (usage thérapeutique).
- MESH :
- anatomopathologie : Tumeurs de l'estomac.
- composition chimique : Dérivés de l'hypromellose, Fibroïne, Glycérol, Hydrogels, Nanoparticules.
- pharmacologie : Antinéoplasiques, Oligopeptides, Xanthones.
- traitement médicamenteux : Tumeurs de l'estomac.
- usage thérapeutique : Antinéoplasiques, Nanoparticules, Xanthones.
- Animaux, Bombyx, Distribution tissulaire, Humains, Lignée cellulaire tumorale, Mâle, Porosité, Souris de lignée BALB C, Souris nude, Température.
English descriptors
- KwdEn :
- Animals (MeSH), Antineoplastic Agents (pharmacology), Antineoplastic Agents (therapeutic use), Bombyx (MeSH), Cell Line, Tumor (MeSH), Fibroins (chemistry), Glycerol (chemistry), Humans (MeSH), Hydrogels (chemistry), Hypromellose Derivatives (chemistry), Male (MeSH), Mice, Inbred BALB C (MeSH), Mice, Nude (MeSH), Nanoparticles (chemistry), Nanoparticles (ultrastructure), Oligopeptides (pharmacology), Porosity (MeSH), Stomach Neoplasms (drug therapy), Stomach Neoplasms (pathology), Temperature (MeSH), Tissue Distribution (MeSH), Xanthones (pharmacology), Xanthones (therapeutic use).
- MESH :
- chemical , chemistry : Fibroins, Glycerol, Hydrogels, Hypromellose Derivatives.
- chemical , pharmacology : Antineoplastic Agents, Oligopeptides, Xanthones.
- chemical , therapeutic use : Antineoplastic Agents, Xanthones.
- chemistry : Nanoparticles.
- drug therapy : Stomach Neoplasms.
- pathology : Stomach Neoplasms.
- ultrastructure : Nanoparticles.
- Animals, Bombyx, Cell Line, Tumor, Humans, Male, Mice, Inbred BALB C, Mice, Nude, Porosity, Temperature, Tissue Distribution.
Abstract
Introduction
Gambogic acid (GA) is proved to have anti-tumor effects on gastric cancer. Due to poor solubility, non-specific biological distribution, toxicity to normal tissues and short half-life, it is hard to be applied into the clinic. To overcome these issues, we developed a thermosensitive and injectable hydrogel composed of hydroxypropyl cellulose, silk fibroin and glycerol, with short gelling time, good compatibility and sustained release, and demonstrated that the hydrogel packaged with gambogic acid nanoparticles (GA-NPs) and tumor-penetrating peptide iRGD could improve the anti-tumor activity.
Methods
The Gelling time and micropore size of the hydrogels were regulated through different concentrations of glycerol. Controlled release characteristics of the hydrogels were evaluated with a real-time near-infrared fluorescence imaging system. Location of nanoparticles from different carriers was traced by confocal laser scanning microscopy. The in vivo antitumor activity of the hydrogels packaging GA-NPs and iRGD was evaluated by investigating tumor volume and tumor size.
Results
The thermo-sensitive properties of hydrogels were characterized by 3-4 min, 37°C, when glycerol concentration was 20%. The hydrogels physically packaged with GA-NPs and iRGD showed higher fluorescence intensity than other groups. The in vivo study indicated that the co-administration of GA-NPs and iRGD by hydrogels had higher antitumor activity than the GA-loaded hydrogels and free GA combining with iRGD. Free GA group showed few antitumor effects. Compared with the control group, the body weight in other groups had no obvious change, and the count of leukocytes and hemoglobin was slightly decreased.
Discussion
The hydrogel constructed iRGD and GA-NPs exerted an effective anti-tumor effect possibly due to retention effect, local administration and continuous sustained release of iRGD promoting the penetration of nanoparticles into a deep part of tumors. The delivery system showed little systemic toxicity and would provide a promising strategy to improve anti-gastric cancer efficacy.
DOI: 10.2147/IJN.S231448
PubMed: 32099362
PubMed Central: PMC6999774
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer.</title><author><name sortKey="Zhang, Dinghu" sort="Zhang, Dinghu" uniqKey="Zhang D" first="Dinghu" last="Zhang">Dinghu Zhang</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou</wicri:regionArea><placeName><settlement type="city">Hangzhou</settlement><region type="province">Zhejiang</region></placeName></affiliation></author><author><name sortKey="Chu, Yanhong" sort="Chu, Yanhong" uniqKey="Chu Y" first="Yanhong" last="Chu">Yanhong Chu</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Qian, Hanqing" sort="Qian, Hanqing" uniqKey="Qian H" first="Hanqing" last="Qian">Hanqing Qian</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Qian, Lingyu" sort="Qian, Lingyu" uniqKey="Qian L" first="Lingyu" last="Qian">Lingyu Qian</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Shao, Jie" sort="Shao, Jie" uniqKey="Shao J" first="Jie" last="Shao">Jie Shao</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Qiuping" sort="Xu, Qiuping" uniqKey="Xu Q" first="Qiuping" last="Xu">Qiuping Xu</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Yu, Lixia" sort="Yu, Lixia" uniqKey="Yu L" first="Lixia" last="Yu">Lixia Yu</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Li, Rutian" sort="Li, Rutian" uniqKey="Li R" first="Rutian" last="Li">Rutian Li</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Quanan" sort="Zhang, Quanan" uniqKey="Zhang Q" first="Quanan" last="Zhang">Quanan Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Jiangning Hospital, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Jiangning Hospital, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Wu, Fenglei" sort="Wu, Fenglei" uniqKey="Wu F" first="Fenglei" last="Wu">Fenglei Wu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang</wicri:regionArea><wicri:noRegion>Lianyungang</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Baorui" sort="Liu, Baorui" uniqKey="Liu B" first="Baorui" last="Liu">Baorui Liu</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Qin" sort="Liu, Qin" uniqKey="Liu Q" first="Qin" last="Liu">Qin Liu</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32099362</idno><idno type="pmid">32099362</idno><idno type="doi">10.2147/IJN.S231448</idno><idno type="pmc">PMC6999774</idno><idno type="wicri:Area/Main/Corpus">000078</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000078</idno><idno type="wicri:Area/Main/Curation">000078</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000078</idno><idno type="wicri:Area/Main/Exploration">000078</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer.</title><author><name sortKey="Zhang, Dinghu" sort="Zhang, Dinghu" uniqKey="Zhang D" first="Dinghu" last="Zhang">Dinghu Zhang</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou</wicri:regionArea><placeName><settlement type="city">Hangzhou</settlement><region type="province">Zhejiang</region></placeName></affiliation></author><author><name sortKey="Chu, Yanhong" sort="Chu, Yanhong" uniqKey="Chu Y" first="Yanhong" last="Chu">Yanhong Chu</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Qian, Hanqing" sort="Qian, Hanqing" uniqKey="Qian H" first="Hanqing" last="Qian">Hanqing Qian</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Qian, Lingyu" sort="Qian, Lingyu" uniqKey="Qian L" first="Lingyu" last="Qian">Lingyu Qian</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Shao, Jie" sort="Shao, Jie" uniqKey="Shao J" first="Jie" last="Shao">Jie Shao</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Qiuping" sort="Xu, Qiuping" uniqKey="Xu Q" first="Qiuping" last="Xu">Qiuping Xu</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Yu, Lixia" sort="Yu, Lixia" uniqKey="Yu L" first="Lixia" last="Yu">Lixia Yu</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Li, Rutian" sort="Li, Rutian" uniqKey="Li R" first="Rutian" last="Li">Rutian Li</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Quanan" sort="Zhang, Quanan" uniqKey="Zhang Q" first="Quanan" last="Zhang">Quanan Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Jiangning Hospital, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Jiangning Hospital, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Wu, Fenglei" sort="Wu, Fenglei" uniqKey="Wu F" first="Fenglei" last="Wu">Fenglei Wu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang</wicri:regionArea><wicri:noRegion>Lianyungang</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Baorui" sort="Liu, Baorui" uniqKey="Liu B" first="Baorui" last="Liu">Baorui Liu</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Qin" sort="Liu, Qin" uniqKey="Liu Q" first="Qin" last="Liu">Qin Liu</name><affiliation wicri:level="1"><nlm:affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing</wicri:regionArea><wicri:noRegion>Nanjing</wicri:noRegion></affiliation></author></analytic><series><title level="j">International journal of nanomedicine</title><idno type="eISSN">1178-2013</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Antineoplastic Agents (pharmacology)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Bombyx (MeSH)</term><term>Cell Line, Tumor (MeSH)</term><term>Fibroins (chemistry)</term><term>Glycerol (chemistry)</term><term>Humans (MeSH)</term><term>Hydrogels (chemistry)</term><term>Hypromellose Derivatives (chemistry)</term><term>Male (MeSH)</term><term>Mice, Inbred BALB C (MeSH)</term><term>Mice, Nude (MeSH)</term><term>Nanoparticles (chemistry)</term><term>Nanoparticles (ultrastructure)</term><term>Oligopeptides (pharmacology)</term><term>Porosity (MeSH)</term><term>Stomach Neoplasms (drug therapy)</term><term>Stomach Neoplasms (pathology)</term><term>Temperature (MeSH)</term><term>Tissue Distribution (MeSH)</term><term>Xanthones (pharmacology)</term><term>Xanthones (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Antinéoplasiques (pharmacologie)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Bombyx (MeSH)</term><term>Distribution tissulaire (MeSH)</term><term>Dérivés de l'hypromellose (composition chimique)</term><term>Fibroïne (composition chimique)</term><term>Glycérol (composition chimique)</term><term>Humains (MeSH)</term><term>Hydrogels (composition chimique)</term><term>Lignée cellulaire tumorale (MeSH)</term><term>Mâle (MeSH)</term><term>Nanoparticules (composition chimique)</term><term>Nanoparticules (ultrastructure)</term><term>Oligopeptides (pharmacologie)</term><term>Porosité (MeSH)</term><term>Souris de lignée BALB C (MeSH)</term><term>Souris nude (MeSH)</term><term>Température (MeSH)</term><term>Tumeurs de l'estomac (anatomopathologie)</term><term>Tumeurs de l'estomac (traitement médicamenteux)</term><term>Xanthones (pharmacologie)</term><term>Xanthones (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Fibroins</term><term>Glycerol</term><term>Hydrogels</term><term>Hypromellose Derivatives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents</term><term>Oligopeptides</term><term>Xanthones</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Xanthones</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs de l'estomac</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Dérivés de l'hypromellose</term><term>Fibroïne</term><term>Glycérol</term><term>Hydrogels</term><term>Nanoparticules</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Stomach Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Stomach Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques</term><term>Oligopeptides</term><term>Xanthones</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs de l'estomac</term></keywords><keywords scheme="MESH" qualifier="ultrastructure" xml:lang="en"><term>Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Nanoparticules</term><term>Xanthones</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Bombyx</term><term>Cell Line, Tumor</term><term>Humans</term><term>Male</term><term>Mice, Inbred BALB C</term><term>Mice, Nude</term><term>Porosity</term><term>Temperature</term><term>Tissue Distribution</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Bombyx</term><term>Distribution tissulaire</term><term>Humains</term><term>Lignée cellulaire tumorale</term><term>Mâle</term><term>Porosité</term><term>Souris de lignée BALB C</term><term>Souris nude</term><term>Température</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>Introduction</b></p><p>Gambogic acid (GA) is proved to have anti-tumor effects on gastric cancer. Due to poor solubility, non-specific biological distribution, toxicity to normal tissues and short half-life, it is hard to be applied into the clinic. To overcome these issues, we developed a thermosensitive and injectable hydrogel composed of hydroxypropyl cellulose, silk fibroin and glycerol, with short gelling time, good compatibility and sustained release, and demonstrated that the hydrogel packaged with gambogic acid nanoparticles (GA-NPs) and tumor-penetrating peptide iRGD could improve the anti-tumor activity.</p></div><div type="abstract" xml:lang="en"><p><b>Methods</b></p><p>The Gelling time and micropore size of the hydrogels were regulated through different concentrations of glycerol. Controlled release characteristics of the hydrogels were evaluated with a real-time near-infrared fluorescence imaging system. Location of nanoparticles from different carriers was traced by confocal laser scanning microscopy. The in vivo antitumor activity of the hydrogels packaging GA-NPs and iRGD was evaluated by investigating tumor volume and tumor size.</p></div><div type="abstract" xml:lang="en"><p><b>Results</b></p><p>The thermo-sensitive properties of hydrogels were characterized by 3-4 min, 37°C, when glycerol concentration was 20%. The hydrogels physically packaged with GA-NPs and iRGD showed higher fluorescence intensity than other groups. The in vivo study indicated that the co-administration of GA-NPs and iRGD by hydrogels had higher antitumor activity than the GA-loaded hydrogels and free GA combining with iRGD. Free GA group showed few antitumor effects. Compared with the control group, the body weight in other groups had no obvious change, and the count of leukocytes and hemoglobin was slightly decreased.</p></div><div type="abstract" xml:lang="en"><p><b>Discussion</b></p><p>The hydrogel constructed iRGD and GA-NPs exerted an effective anti-tumor effect possibly due to retention effect, local administration and continuous sustained release of iRGD promoting the penetration of nanoparticles into a deep part of tumors. The delivery system showed little systemic toxicity and would provide a promising strategy to improve anti-gastric cancer efficacy.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32099362</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1178-2013</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>International journal of nanomedicine</Title><ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation></Journal><ArticleTitle>Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer.</ArticleTitle><Pagination><MedlinePgn>735-747</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S231448</ELocationID><Abstract><AbstractText Label="Introduction" NlmCategory="UNASSIGNED">Gambogic acid (GA) is proved to have anti-tumor effects on gastric cancer. Due to poor solubility, non-specific biological distribution, toxicity to normal tissues and short half-life, it is hard to be applied into the clinic. To overcome these issues, we developed a thermosensitive and injectable hydrogel composed of hydroxypropyl cellulose, silk fibroin and glycerol, with short gelling time, good compatibility and sustained release, and demonstrated that the hydrogel packaged with gambogic acid nanoparticles (GA-NPs) and tumor-penetrating peptide iRGD could improve the anti-tumor activity.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">The Gelling time and micropore size of the hydrogels were regulated through different concentrations of glycerol. Controlled release characteristics of the hydrogels were evaluated with a real-time near-infrared fluorescence imaging system. Location of nanoparticles from different carriers was traced by confocal laser scanning microscopy. The in vivo antitumor activity of the hydrogels packaging GA-NPs and iRGD was evaluated by investigating tumor volume and tumor size.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">The thermo-sensitive properties of hydrogels were characterized by 3-4 min, 37°C, when glycerol concentration was 20%. The hydrogels physically packaged with GA-NPs and iRGD showed higher fluorescence intensity than other groups. The in vivo study indicated that the co-administration of GA-NPs and iRGD by hydrogels had higher antitumor activity than the GA-loaded hydrogels and free GA combining with iRGD. Free GA group showed few antitumor effects. Compared with the control group, the body weight in other groups had no obvious change, and the count of leukocytes and hemoglobin was slightly decreased.</AbstractText><AbstractText Label="Discussion" NlmCategory="UNASSIGNED">The hydrogel constructed iRGD and GA-NPs exerted an effective anti-tumor effect possibly due to retention effect, local administration and continuous sustained release of iRGD promoting the penetration of nanoparticles into a deep part of tumors. The delivery system showed little systemic toxicity and would provide a promising strategy to improve anti-gastric cancer efficacy.</AbstractText><CopyrightInformation>© 2020 Zhang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Dinghu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chu</LastName><ForeName>Yanhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Hanqing</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7743-6019</Identifier><AffiliationInfo><Affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Lingyu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qiuping</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lixia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rutian</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Quanan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Oncology, Jiangning Hospital, Nanjing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Fenglei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Oncology, Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Baorui</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Int J Nanomedicine</MedlineTA><NlmUniqueID>101263847</NlmUniqueID><ISSNLinking>1176-9114</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020100">Hydrogels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C569656">N-end cysteine peptide tumor-homing peptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044004">Xanthones</NameOfSubstance></Chemical><Chemical><RegistryNumber>3NXW29V3WO</RegistryNumber><NameOfSubstance UI="D065347">Hypromellose Derivatives</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N585K83U2</RegistryNumber><NameOfSubstance UI="C052659">gambogic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-76-5</RegistryNumber><NameOfSubstance UI="D005349">Fibroins</NameOfSubstance></Chemical><Chemical><RegistryNumber>PDC6A3C0OX</RegistryNumber><NameOfSubstance UI="D005990">Glycerol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012831" MajorTopicYN="N">Bombyx</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005349" MajorTopicYN="N">Fibroins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005990" MajorTopicYN="N">Glycerol</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020100" MajorTopicYN="N">Hydrogels</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065347" MajorTopicYN="N">Hypromellose Derivatives</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016062" MajorTopicYN="N">Porosity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013696" MajorTopicYN="Y">Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044004" MajorTopicYN="N">Xanthones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">gambogic acid</Keyword><Keyword MajorTopicYN="N">gastric cancer</Keyword><Keyword MajorTopicYN="N">hydrogel</Keyword><Keyword MajorTopicYN="N">iRGD</Keyword><Keyword MajorTopicYN="N">nanoparticles</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>09</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>01</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32099362</ArticleId><ArticleId IdType="doi">10.2147/IJN.S231448</ArticleId><ArticleId IdType="pii">231448</ArticleId><ArticleId IdType="pmc">PMC6999774</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Drug Discov Today. 2016 Jan;21(1):157-166</Citation><ArticleIdList><ArticleId IdType="pubmed">26563428</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2015 Jun 28;208:76-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25747144</ArticleId></ArticleIdList></Reference><Reference><Citation>J Res Natl Inst Stand Technol. 2010 Jul;115(4):277-290</Citation><ArticleIdList><ArticleId IdType="pubmed">21037803</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Mater Res A. 2014 Mar;102(3):808-17</Citation><ArticleIdList><ArticleId IdType="pubmed">23589413</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 2014 Mar 18;110(6):1481-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24556620</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cancer. 2002 Mar;38(4):602-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11872356</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Appl Mater Interfaces. 2013 Jun 26;5(12):5592-600</Citation><ArticleIdList><ArticleId IdType="pubmed">23734910</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbohydr Polym. 2014 Jan;99:630-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24274553</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Nanomedicine. 2014 Jul 10;9:3313-24</Citation><ArticleIdList><ArticleId IdType="pubmed">25045262</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2015 Aug 28;212:59-69</Citation><ArticleIdList><ArticleId IdType="pubmed">26071630</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanomedicine. 2012 May;8(4):432-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21856276</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Dev Res. 2015 May;76(3):132-42</Citation><ArticleIdList><ArticleId IdType="pubmed">25959042</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2003 Jan;24(2):357-65</Citation><ArticleIdList><ArticleId IdType="pubmed">12419638</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Cell Biol. 2012 Dec;90(6):718-30</Citation><ArticleIdList><ArticleId IdType="pubmed">23194187</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharm Dev Technol. 2018 Jan;23(1):33-40</Citation><ArticleIdList><ArticleId IdType="pubmed">29069711</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pharm. 2017 Apr 30;522(1-2):110-118</Citation><ArticleIdList><ArticleId IdType="pubmed">28242375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2015 Aug 1;75(15):3147-54</Citation><ArticleIdList><ArticleId IdType="pubmed">26239478</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2010 May 21;328(5981):1031-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20378772</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pharm. 2015 Oct 15;494(1):264-70</Citation><ArticleIdList><ArticleId IdType="pubmed">26283278</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Nanotechnol. 2014 Sep;10(9):1841-62</Citation><ArticleIdList><ArticleId IdType="pubmed">25992443</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2014 Oct;35(30):8735-47</Citation><ArticleIdList><ArticleId IdType="pubmed">25023394</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2017 Jul 25;8(1):124</Citation><ArticleIdList><ArticleId IdType="pubmed">28743858</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2017 Nov 2;13(11):2561-2574</Citation><ArticleIdList><ArticleId IdType="pubmed">28857666</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Mater. 2012 Jul 24;24(28):3747-56</Citation><ArticleIdList><ArticleId IdType="pubmed">22550056</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Med (Berl). 2015 Sep;93(9):991-1001</Citation><ArticleIdList><ArticleId IdType="pubmed">25869026</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Biother Radiopharm. 2012 Jun;27(5):299-306</Citation><ArticleIdList><ArticleId IdType="pubmed">22444164</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Deliv. 2016 May;23(4):1232-41</Citation><ArticleIdList><ArticleId IdType="pubmed">26701717</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2016 Dec 10;243:29-42</Citation><ArticleIdList><ArticleId IdType="pubmed">27693428</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumour Biol. 2017 Jul;39(7):1010428317714626</Citation><ArticleIdList><ArticleId IdType="pubmed">28671042</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanomedicine. 2012 Nov;8(8):1263-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22841914</ArticleId></ArticleIdList></Reference><Reference><Citation>Colloids Surf B Biointerfaces. 2013 Dec 1;112:30-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23939422</ArticleId></ArticleIdList></Reference><Reference><Citation>Macromol Biosci. 2015 Mar;15(3):372-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25367414</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2011 May 10;151(3):239-45</Citation><ArticleIdList><ArticleId IdType="pubmed">21362447</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Drug Deliv Rev. 2018 Mar 1;127:167-184</Citation><ArticleIdList><ArticleId IdType="pubmed">29567395</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Appl Mater Interfaces. 2015 Dec 16;7(49):27458-66</Citation><ArticleIdList><ArticleId IdType="pubmed">26633260</ArticleId></ArticleIdList></Reference><Reference><Citation>Mater Sci Eng C Mater Biol Appl. 2016 May;62:927-42</Citation><ArticleIdList><ArticleId IdType="pubmed">26952500</ArticleId></ArticleIdList></Reference><Reference><Citation>AAPS PharmSciTech. 2017 Aug;18(6):1987-1997</Citation><ArticleIdList><ArticleId IdType="pubmed">27933587</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Today. 2015 Jul;20(7):848-55</Citation><ArticleIdList><ArticleId IdType="pubmed">25908576</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Biomater. 2016 Feb;31:156-166</Citation><ArticleIdList><ArticleId IdType="pubmed">26621695</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Mater Res A. 2015 Jul;103(7):2225-35</Citation><ArticleIdList><ArticleId IdType="pubmed">25345387</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Cell. 2009 Dec 8;16(6):510-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19962669</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Appl Mater Interfaces. 2017 Jan 18;9(2):1280-1292</Citation><ArticleIdList><ArticleId IdType="pubmed">28009503</ArticleId></ArticleIdList></Reference><Reference><Citation>BioDrugs. 2002;16(5):339-47</Citation><ArticleIdList><ArticleId IdType="pubmed">12408738</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncol Lett. 2017 Jan;13(1):37-44</Citation><ArticleIdList><ArticleId IdType="pubmed">28123519</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Mater Res A. 2015 Oct;103(10):3374-85</Citation><ArticleIdList><ArticleId IdType="pubmed">25856734</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharm Biopharm. 2015 Sep;95(Pt B):271-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25592326</ArticleId></ArticleIdList></Reference><Reference><Citation>J Tissue Eng Regen Med. 2017 May;11(5):1532-1541</Citation><ArticleIdList><ArticleId IdType="pubmed">26053955</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ther. 2014 Aug;21(8):767-74</Citation><ArticleIdList><ArticleId IdType="pubmed">24942629</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country><region><li>Zhejiang</li></region><settlement><li>Hangzhou</li></settlement></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Zhang, Dinghu" sort="Zhang, Dinghu" uniqKey="Zhang D" first="Dinghu" last="Zhang">Dinghu Zhang</name></noRegion><name sortKey="Chu, Yanhong" sort="Chu, Yanhong" uniqKey="Chu Y" first="Yanhong" last="Chu">Yanhong Chu</name><name sortKey="Li, Rutian" sort="Li, Rutian" uniqKey="Li R" first="Rutian" last="Li">Rutian Li</name><name sortKey="Liu, Baorui" sort="Liu, Baorui" uniqKey="Liu B" first="Baorui" last="Liu">Baorui Liu</name><name sortKey="Liu, Qin" sort="Liu, Qin" uniqKey="Liu Q" first="Qin" last="Liu">Qin Liu</name><name sortKey="Qian, Hanqing" sort="Qian, Hanqing" uniqKey="Qian H" first="Hanqing" last="Qian">Hanqing Qian</name><name sortKey="Qian, Lingyu" sort="Qian, Lingyu" uniqKey="Qian L" first="Lingyu" last="Qian">Lingyu Qian</name><name sortKey="Shao, Jie" sort="Shao, Jie" uniqKey="Shao J" first="Jie" last="Shao">Jie Shao</name><name sortKey="Wu, Fenglei" sort="Wu, Fenglei" uniqKey="Wu F" first="Fenglei" last="Wu">Fenglei Wu</name><name sortKey="Xu, Qiuping" sort="Xu, Qiuping" uniqKey="Xu Q" first="Qiuping" last="Xu">Qiuping Xu</name><name sortKey="Yu, Lixia" sort="Yu, Lixia" uniqKey="Yu L" first="Lixia" last="Yu">Lixia Yu</name><name sortKey="Zhang, Dinghu" sort="Zhang, Dinghu" uniqKey="Zhang D" first="Dinghu" last="Zhang">Dinghu Zhang</name><name sortKey="Zhang, Quanan" sort="Zhang, Quanan" uniqKey="Zhang Q" first="Quanan" last="Zhang">Quanan Zhang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000131 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000131 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= BiopestPeptidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32099362
|texte= Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32099362" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a BiopestPeptidV1
| This area was generated with Dilib version V0.6.38. |  |